- Senior Research Fellow, Oxford Martin School
Andrew Farlow has nearly 20 years experience researching and advising on the development, deployment, and financing of vaccines (for TB, malaria, chickenpox, shingles, dengue, HIV, pandemic influenza, and COVID-19). He is head of Global Health Initiatives for Oxford in Berlin, convener of its COVID-19 Science and Policy Open Forum (bringing together scientists, policymakers, and the public for discussion and consensus building), and co-chairs the Supply & Market Dynamics and Medicine Quality Working Group of the COVID-19 Clinical Research Coalition, exploring how to achieve equitable access to, and maintain the quality of, COVID-19 interventions.
He is Visiting Professor of the Institute of Drugs Technology, Oswaldo Cruz Foundation, Brazil, fostering a partnership with researchers at Oxford, the Royal Botanic Gardens Kew, a range of German research institutes, and other global partners, to discover and develop novel priority medicines based on natural molecules, especially from plants, fungi, and algae, to tackle global health threats while protecting biodiversity. He has lectured at over fifty Chinese universities, including on planetary health, and has created a network of twenty research institutes (in the UK, China, Brasil, India, Germany, and Italy) to investigate the impact of pollution on the human microbiome over the life course (and its consequences for antimicrobial resistance, immunity, and pathogen spread), cleaner technologies, and improved urban design to protect human health.
He is Senior Fellow of the Oxford Martin School, where he has been Co-PI on the Programme on Vaccines. He has been Senior Research Fellow of Oxford’s Saïd Business School, Senior Research Fellow of the Department of Zoology, and Research Fellow of Oriel College, where he was Director of Studies in Economics for six years. He has mentored dozens of young scholars on a wide range of health-related projects, and has made young-researcher engagement a key part of Oxford in Berlin activities, including of the new Oxford-Berlin Centre for Advanced Studies and the Berlin Open Science Centre. He has advised many public- and private-sector organizations, including the WHO, UNDP, TB Alliance, Stop TB, Aeras, JCVI, DFID, DNDi, the UK Treasury, Bill and Melinda Gates Foundation, World Bank, Oxfam, Médecins Sans Frontières, Global Alliance for Vaccines and Immunization, Action Aid, etc.